U.S. Natural Gas Futures Drop Below $3 for First Time Since 2012

Gilead Sciences to Release Fourth Quarter and Year End 2012 Financial Results on Monday, February 4, 2013

  Gilead Sciences to Release Fourth Quarter and Year End 2012 Financial
  Results on Monday, February 4, 2013

                    Conference Call and Webcast to Follow

Business Wire

FOSTER CITY, Calif. -- January 28, 2013

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter
and year end 2012 financial results will be released on Monday, February 4, at
4:05 p.m. Eastern Time. At 4:30 p.m. Eastern Time, Gilead’s management will
host a conference call to discuss the company’s financial results for the
fourth quarter and full year 2012 and provide a general business update and
financial guidance for 2013. The conference call will be accessible via the
internet from the company’s website.

To access the webcast link, log on to Please connect to the
company’s website at least 15 minutes prior to the conference call to ensure
adequate time for any software download that may be required to listen to the
webcast. Alternatively, please call 1-800-901-5231 (U.S.) or 1-617-786-2961
(international) and dial the participant passcode 49057415 to access the call.
Telephone replay will be available approximately two hours after the call
through 11:59 p.m. Eastern Time, February 7, 2013. To access the replay,
please call 1-888-286-8010 (U.S.) or 1-617-801-6888 (international) and dial
the participant passcode 15606712. The webcast will be archived on for one year.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and
commercializes innovative therapeutics in areas of unmet medical need. The
company’s mission is to advance the care of patients suffering from
life-threatening diseases worldwide. Headquartered in Foster City, California,
Gilead has operations in North America, Europe and Asia Pacific.

 For more information on Gilead Sciences, please visit or call
   the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).


Gilead Sciences, Inc.
Patrick O’Brien, 650-522-1936 (Investor Relations)
Press spacebar to pause and continue. Press esc to stop.